Vaughan David Investments LLC IL lower its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 89.9% throughout the 2nd quarter, Holdings Channel studies. The fund owned 59,578 shares of the biopharmaceutical firm’s inventory after promoting 530,950 shares throughout the interval. Vaughan David Investments LLC IL’s holdings in Bristol-Myers Squibb had been value $2,474,000 as of its most up-to-date submitting with the Securities and Change Fee.
Different institutional buyers and hedge funds have additionally modified their holdings of the corporate. Angeles Wealth Administration LLC raised its holdings in Bristol-Myers Squibb by 4.5% within the 2nd quarter. Angeles Wealth Administration LLC now owns 9,195 shares of the biopharmaceutical firm’s inventory value $382,000 after buying a further 392 shares throughout the interval. MGO One Seven LLC raised its stake in shares of Bristol-Myers Squibb by 7.2% within the second quarter. MGO One Seven LLC now owns 24,427 shares of the biopharmaceutical firm’s inventory value $1,014,000 after shopping for a further 1,632 shares throughout the interval. Headlands Applied sciences LLC bought a brand new place in shares of Bristol-Myers Squibb throughout the 2nd quarter valued at about $4,957,000. Van Hulzen Asset Administration LLC elevated its holdings in Bristol-Myers Squibb by 57.2% within the 2nd quarter. Van Hulzen Asset Administration LLC now owns 8,480 shares of the biopharmaceutical firm’s inventory value $352,000 after buying a further 3,087 shares within the final quarter. Lastly, Daiwa Securities Group Inc. raised its stake in Bristol-Myers Squibb by 19.1% throughout the 2nd quarter. Daiwa Securities Group Inc. now owns 251,882 shares of the biopharmaceutical firm’s inventory value $10,461,000 after buying a further 40,369 shares throughout the interval. Hedge funds and different institutional buyers personal 76.41% of the corporate’s inventory.
Analysts Set New Value Targets
Numerous equities analysts have weighed in on BMY shares. TD Cowen upped their worth goal on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the inventory a “maintain” score in a analysis report on Monday, August twelfth. Cantor Fitzgerald reaffirmed a “impartial” score and issued a $45.00 goal worth on shares of Bristol-Myers Squibb in a report on Monday, July twenty second. Jefferies Monetary Group raised their worth goal on Bristol-Myers Squibb from $49.00 to $51.00 and gave the corporate a “maintain” score in a report on Wednesday, August twenty eighth. Deutsche Financial institution Aktiengesellschaft dropped their worth goal on Bristol-Myers Squibb from $53.00 to $45.00 and set a “maintain” score for the corporate in a analysis be aware on Tuesday, July twenty third. Lastly, StockNews.com raised Bristol-Myers Squibb from a “purchase” score to a “strong-buy” score in a analysis be aware on Monday, July twenty ninth. Two analysis analysts have rated the inventory with a promote score, 13 have assigned a maintain score, two have issued a purchase score and one has given a robust purchase score to the inventory. In accordance with MarketBeat, the corporate at the moment has a mean score of “Maintain” and a consensus goal worth of $54.67.
Get Our Newest Analysis Report on BMY
Bristol-Myers Squibb Inventory Down 1.4 %
NYSE BMY opened at $48.59 on Thursday. The inventory has a 50 day shifting common worth of $46.44 and a 200-day shifting common worth of $46.53. Bristol-Myers Squibb has a one 12 months low of $39.35 and a one 12 months excessive of $61.01. The corporate has a market capitalization of $98.50 billion, a P/E ratio of -15.67, a P/E/G ratio of 12.62 and a beta of 0.46. The corporate has a debt-to-equity ratio of two.86, a fast ratio of 1.02 and a present ratio of 1.16.
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) final launched its quarterly earnings information on Friday, July twenty sixth. The biopharmaceutical firm reported $2.07 EPS for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a damaging web margin of 14.06% and a constructive return on fairness of 12.51%. The enterprise had income of $12.20 billion throughout the quarter, in comparison with analyst estimates of $11.54 billion. Throughout the identical quarter final 12 months, the enterprise earned $1.75 earnings per share. Bristol-Myers Squibb’s quarterly income was up 8.7% in comparison with the identical quarter final 12 months. As a bunch, equities analysts predict that Bristol-Myers Squibb will put up 0.77 EPS for the present fiscal 12 months.
Bristol-Myers Squibb Proclaims Dividend
The enterprise additionally lately disclosed a quarterly dividend, which can be paid on Friday, November 1st. Shareholders of report on Friday, October 4th can be paid a dividend of $0.60 per share. The ex-dividend date is Friday, October 4th. This represents a $2.40 annualized dividend and a yield of 4.94%. Bristol-Myers Squibb’s payout ratio is at the moment -77.42%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Firm discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical merchandise worldwide. It presents merchandise for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience ailments. The corporate’s merchandise embody Eliquis for discount in threat of stroke/systemic embolism in non-valvular atrial fibrillation, and for the remedy of DVT/PE; Opdivo for numerous anti-cancer indications, together with bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, abdomen and esophageal most cancers; Pomalyst/Imnovid for a number of myeloma; Orencia for energetic rheumatoid arthritis and psoriatic arthritis; and Sprycel for the remedy of Philadelphia chromosome-positive continual myeloid leukemia.
Additional Studying
Need to see what different hedge funds are holding BMY? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Obtain Information & Scores for Bristol-Myers Squibb Every day – Enter your e-mail handle beneath to obtain a concise each day abstract of the most recent information and analysts’ rankings for Bristol-Myers Squibb and associated firms with MarketBeat.com’s FREE each day e-mail e-newsletter.
